New drugs in breast cancer

Bibliography

• PUJOL P, HILSENBECK SG, CHAMNESS GC et al: Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer (1994) 74: 1601-1606.
   Google Scholar
• MILLER WR: Estrogens and endocrine therapy for breast cancer. In: Estrogen and Breast Cancer. WR Miller (Ed.) RH Landes & Co., Austin, Texas (1996):125–150.
   Google Scholar
• NISSEN-MEYER R: Castration as part of the primary treatment for operable female breast cancer. Acta Radiologica Suppl (1965) 249:1–133.
   Google Scholar
• HARVEY HA, LIPTON A, MAX DT et al.: Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer. j Obi arca. (1985) 3:1068–1072.
   Google Scholar
• MILLER WR: Sources of estrogen and sites of biosynthesis. In: Estrogen and Breast Cancer WR Miller (Ed.) RH Landes & Co. Austin, Texas (1996):75–94.
   Google Scholar
• SIMPSON E, RUBIN G, CLYNE C, ROBERTSON K, O'DONNELL L, DAVIS S, JONES M: Local estrogen biosynthesis in males and females. Endocrine Related Cancer (1999) 6:131–137.
   PubMed Web of Science ®Google Scholar
• JORDAN VC, PARKER CJ, MORROW M: Update: breast cancer treatment and prevention with antioestrogens in the 1990s. Eridocr. Rev (1993) 1:82–85
   Google Scholar
• MILLER WR: Aromotase inhibitors in the treatment of advanced breast cancer. Cancer Treat. Rev(1989) 16:83–93.
   PubMed Web of Science ®Google Scholar
• MILLER WR: Aromatase inhibitors and breast cancer. Cancer Treat. Rev (1997) 23:171–187.
   PubMed Web of Science ®Google Scholar
• CLEMETT D, LAMB HM: Exemestane: Areview. Drugs (2000) 59 (In Press).
   Google Scholar
• JOHNSTON JO, METCALF BW: Aromatase: a target enzyme in breast cancer. In: Novel Approaches to Cancer Chemotherapy Academic Press, London (1984)307–328.
   Google Scholar
• SANTEN RJ, MISBIN RI: Aminoglutethimide: review of pharmacology and clinical use. Phannacotherapy (1981) 1:95–120.
   PubMed Web of Science ®Google Scholar
• BHATNAGAR AS, HAUSLER A, SCHIEWECK KL, LANG M, BOWMAN R: Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. j Steroid Biochein. Mal Biol. (1990) 37:1021–1027.
   PubMed Web of Science ®Google Scholar
• YATES RA, DOWSETT M, FISHER GV, SELEN SA, VVYLD PJ: Arimidex (ZD1033): A selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br. J. Cancer (1996) 73:543–548.
   PubMed Web of Science ®Google Scholar
• LONNING PE: Pharmacology of new aromatase inhibitors. The Breast (1996) 5:202–208.
   Web of Science ®Google Scholar
• DEMERS LM, LIPTON A, HARVEY HA, KAMBIC KB, GROSSBERG H, BRADY C, SANTEN RJ: The efficacy of CG520267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. j Steroid Biochein. (1993) 44:687–691.
   Google Scholar
• MILLER WR: In vitro, and in vivo effects of 4-hydroxyandrostenedione on steroid and tumour metabolism. In: RC Coombes, M Dowsett (Eds) 4-Hydroxyandrostenedione - A new Approach to Hormone-Dependent Cancer. London; Royal Society of Medidne Services Ltd. International Congress and Symposium Series (1992):45–50.
   Google Scholar
• JAMES VHT, REED MJ, ADAMS EF et al.: Oestrogen uptake and metabolism in vivo. Proceedings of the Royal Socieh, of Edinburgh (1989) 95B:185–193.
   Google Scholar
• MILLER WR, MULLEN P, TELFORD J, DIXON JM: Clinical importance of intratumoral aromatase. Breast Cancer Res. Treat (1998) 49:S27–S32.
   Google Scholar
• MILLER WR: Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocrine Related Cancer (1999) 6:187–195.
   PubMed Web of Science ®Google Scholar
• MILLER WR, TELFORD J, LOVE C et al.: Effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast. The Breast (1998) 7:273–276.
   Web of Science ®Google Scholar
• MILLER WR, DIXON JM, GRATTAGE L, STUART M, HOCTIN-BOES G: Effects of neoadjuvant treatment with the aromatase inhibitor, anastrozole (Arimidex'), on peripheral and in situ estrogen synthesis and uptake by breast tissue in postmenopausal women. Breast Cancer Res. Treat (1999) 57:32–32.
   Google Scholar
• WANDER HE, BLOSSEY HCH, NAGEL GA: Aminoglutethemide in the treatment of postmenopausal patients with metastatic breast cancer. Eur. j Cancer Chia. arca (1986) 22:1371–1374.
   Google Scholar
• HARRIS AL, DOWSETT M, JEFFCOATE SL et al: Endocrine and therapeutic effects of aminoglutethemide in premenopausal patients with breast cancer. J ClinEndocrinolMetab (1982) 55:718–720.
   PubMed Web of Science ®Google Scholar
• JOHNSTON SRD, SAC CANI-JOTTIG, SMITH IE et al: ER expression at relapse for response to second line endocrine therapy. Br J Cancer (1997) 7 5(S1):16.
   Google Scholar
• BUZDAR AU, JONAT W, HOWELL A et al.: Anastrozole a potent and selective aromatase inhibitor versus megesterol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two Phase III trials. Cancer (1998) 83:1142–1152.
   PubMed Web of Science ®Google Scholar
• DOMBERNOWSKY P, SMITH I, FALKSON G et al: Letrozole a new aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose-effect and improved efficacy and tolerability compared with megesterol acetate. J Clin. Oricol . (1998) 16:453–461.
   PubMed Web of Science ®Google Scholar
• GERSHANOVICH M, CHAUDRI HA, CAMPOS D et al: Letrozole a new aromatase inhibitor: randomized trial comparing 2.5mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann. Oricol . (1998) 9:639–645.
   Google Scholar
• KAUFMANN M, BAJETTA E, DIRIX LY etal.: Survival advantage of exemestane over megestrol acetate in postmenopausal women with advanced breast cancer refractory to tamoxifen: results of Phase III randomized double-blind study. Proc. Am. Soc. an. arca (1999) 18:109.
   Google Scholar
• THUERLIMANN BJK, NABHOLTZ JM, BONNETERRE J et al.: Preliminary results of two comparative multicentre clinical trials comparing the efficacy and tolerability of arimidex (anastrozole) and tamoxifen in postmenopausal women with advanced breast cancer. The Breast (1999) 8:214.
   Google Scholar
• DIXON JM, LOVE CBD, TUCKERS et al.: Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res. Treat (1997) 46 (Supp0:54.
   Google Scholar
• DIXON JM, RENSHAW L, BELLAMY C, CAMERON DA, MILLER WR, LEONARD RCF: Efficacy of anastrazole as neoadjuvant therapy in postmenopausal women with large operable breast cancers: reductions in tumour volume. Breast (1999) 8:215.
   Google Scholar
• JONES S, BELT R, COOPER B et al: APhase II study of anti-tumour efficacy and safety of exemestane as second-line hormonal treatment of postmenopausal patients with metastatic breast cancer refractory to tamoxifen. Breast Cancer Res. Treat (1998) 50:304.
   Google Scholar
• KVINNSLAND S, ANKER G, DIRIX LY et al.: Activity of exemestane, an irreversible, oral, aromatase inhibitor in metastatic postmenopausal breast cancer patients failing tamoxifen. Eur. j. Cancer (1998) 34\(Suppl. 5):S91.
   Google Scholar
• NUIJTEN M, MEESTER L, WAIBEL F, WAIT S: Cost-effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women the UK. Pharmacoeconomics (1999) 16:379–397.
   PubMed Web of Science ®Google Scholar
• TRICHOPOULOS D, MACMAHON B, COLE P: Menopause and breast cancer risk. SVC/(1972) 48:605–613.
   Google Scholar
• WIENFELD AM: The relationship of cancer of female breast and artificial menopause and menstrual status. Cancer (1956) 9:927–936.
   PubMedGoogle Scholar
• LUBET RA, STEELE VE, CASEBOLT TL, ETO I, KELLOFF GJ, GRUBS CJ: Chemopreventative effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosurea (MNU)-induced mammary tumour model in Sprague-Dawley rats. Carcirlogenesis (1994) 15:2775–2780.
   PubMed Web of Science ®Google Scholar
• YAGER JD, LIEHR JG: Molecular mechanisms of estrogen carcinogenesis. Ann. Rev Pharmacol. Toxicol. (1996) 36:203–232.
   PubMed Web of Science ®Google Scholar
• NABHOLTZ JM, GELMAN K, BONTELBAL M et al.: Multicentre, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. j. Clin. Oncol. (1996) 14:1858–1867.
   PubMed Web of Science ®Google Scholar
• PARIDAENS R, BRUNING E KLIJN T et al.: Taxol versus doxirubicin as first line chemotherapy in advanced breast cancer: An EROTC randomized study with crossover. Eur. J. Cancer (1997) 33:145.
   Google Scholar
• SLEDGE GW, NEUBERG D, INGLE J et al.: A Phase III trial of doxorubicin vs. paclitaxel vs. doxorubicin plus paclitaxel as first line chemotherapy of metastatic breast cancer: an intergroup trial. Proc. Am Soc. Chit. Oncol. (1997) 16: 1 a.
   Google Scholar
• VALERO V, HOLMES E WALTERS RS et al.: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracyclin-resistant metastatic breast cancer. j. Oncol. (1995) 13:2886–2894.
   Google Scholar
• RAVIDIN PM, BURRIS HA, COOK G et al.: Phase II trial of docetaxel in advanced anthracyclin-resistant or anthracenedione- resistant breast cancer. j. Chit. Oncol. (1995) 13:2879–2885.
   PubMedGoogle Scholar
• NABHOLTZ JM, SENN HJ, BEZODA WR et al.: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracyclin-containing chemotherapy. 304 Study Group. J. Chit. Oncol. (1999) 17:1413–1424.
   Google Scholar
• SJOSTROM J, MOURIDSEN H, PLUZANSKA A et al.: Taxotere versus methotrexate-5-flurouracil in patients with advanced anthracyclin resistant breast cancer: Preliminary results of a randomized Phase III study by Scandinavian Breast Cancer Group. Proc. Am Soc. Chit. Oncol. (1998) 17:111a.
   Google Scholar
• CHAN S, FRIERICHS K, NOEL D etal.: A Phase III study of docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed an alkylating containing regimen. Breast Cancer Res. Treat (1997) 46:23.
   Google Scholar
• GIANNI L, MUNZONE E, CAPRI G et al.: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumour efficacy and cardiac effects in a dose-finding and sequence finding study. j. Clin.Oricol. (1995) 13:2688–2699.
   PubMed Web of Science ®Google Scholar
• DIERAS V: Taxanes in combination withdoxorubicin in the treatment of metastatic breast cancer. Semin. Oncol. (1998) 25:18–22.
   PubMedGoogle Scholar
• D'INCALCI M, SCHULLER J, COLOMBO T etal.: Taxoids in combination with anthracyclins and other agents; pharmacokinetic considerations. Semin. Oncol. (1998) 25\(Supp1.13):16–20.
   Google Scholar
• PAGANI 0: Taxoids in combination with epirubicin: search for improved outcomes in breast cancer. Semin. Oncol. (1998) 25:23–26.
   PubMedGoogle Scholar
• NABHOLTZ JM, NORTH S, SMYLIE M etal.: Docetaxel in combination with anthracyclins in the treatment of breast cancer. Semin. Oncol. (2000) 27:11–18.
   Google Scholar
• HENDERSON I C, BERRY D, DEMETRI G et al.: Improved disease free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from escalation of doxorubicin (A) dose level in adjuvant chemotherapy of patients with node positive primary breast cancer. Proc. Am Soc. Clin. Oncol. (1998) 17:101.
   Google Scholar
• SEIDMAN AD: Single agent Paclitaxel in the treatment of breast cancer: Phase I and II development. Semin. Oncol. (1999) 26\(Suppl. 8):14–20.
   Google Scholar
• PICCART MJ, KLIJN J, PARIDAENS R et al.: Steroids do reduce the severity and delay the onset of docetaxel induced fluid retention: final results of a randomized trial of the EORTC investigational Drug Branch for Breast Cancer (IDBBC). Eur. I.Cancer (1995) 31A\(Suppl. 5):575.
   Google Scholar
• COBLEIGH MA, VOGEL CL, TRIPATHY D et al.: Efficacy and safety of Herceptin as a single agent in 222 women HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc. Am. Soc. Chit. Oncol. (1998) 17:97a.
   Google Scholar
• SLAMON D, LEYLAND-JONES B, SHAK S et al.: Addition of Herceptin to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized multinational controlled Phase III trial. Proc. Am. Soc. Clin. Oncol. (1998) 17:98a.
   Google Scholar
• BASELGA J, TRIPATHY D, MANDELSON J et al.: Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/nue overexpressing metastatic breast cancer. j. Clin. Oncol. (1996) 14:737–744.
   PubMed Web of Science ®Google Scholar
• PEGRAM MD, LIPTON A, HAYES DF et al.: Phase II study of receptor enhanced chemosensitivity using recombinant humanised anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. j. Clin. Oncol. (1998) 8:2659–2671.
   Google Scholar
• OSABA D AND BURCHMORE M: Health related Quality of Life in Women With Metastatic Breast Cancer Treated With Trastuzumab (Herceptin). Semin. Oncol. (1999) 26\(Suppl. 12):84–88.
   Google Scholar
• CONTE PF, LATREILLE J, MAURIAC L et al.: Delay in progression of bone metastases in cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial. j Clin. Oncol. (1996) 14:2552–2559.
   PubMed Web of Science ®Google Scholar
• HORTOBAGYI GN, THERIAULT RL, LIPTON A et al.: Long-term prevention of skeletal complications of metastatic breast cancer with Pamidronate. j Chit. Oncol. (1998) 16:2038–2044.
   PubMed Web of Science ®Google Scholar
• THERIAULT RL, LIPTON A, HORTOBAGYI GN et al: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo controlled trial. ..J. OM. Omni (1999) 17:846–854.
   Google Scholar
• PATERSON AHG, POWLES TJ, KANIS JA et al.: Double-bind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Gin Oncel (1993) 11:59–65
   PubMedGoogle Scholar
• VAN HOLTEN-VERZANTVOORT ATM, KROON HM, BIJVOET OLM et al: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J. OM. Omni (1993) 11:491–498.
   Google Scholar
• HILLNER BE, INGLE JN, BERENSON JRet al.: American Society of clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer. J. Gin Omni (2000) 18:1378–1391.
   Google Scholar
• DIEL IJ, SOLOMAYER EF, COSTA SD etal.: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl. J. Med. (1998) 339:357–363.
   Google Scholar
• SAARTO T, BLOMQVIST C, VALIMAKI M et al.: Chemical castration induced by adjuvant cyclophosphomide, methotrexate and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J. Clin. amyl (1997) 15:1341–1347.
   Google Scholar
• POWLES TJ, MCCLOSKEY E, PATERSON AH et al.: Oral clodronate and reduction inloos of bone mineral density in women with operable primary breast cancer. J. Natl. Cancer Inst. (1998) 90:704–708.
   PubMed Web of Science ®Google Scholar
• FISHER B, COSTANTINO JP, WICKERHAM L et al.: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. (1998) 90:1371–1388.
   PubMed Web of Science ®Google Scholar
• GAIL MH, COSTANTINO JP, BRYANT J et al.: Wei911ng the risks and benefits of tamoxifen treatment for preventing breast cancer. J. Natl. Cancer Inst. (1999) 91:1829–1846.
   PubMed Web of Science ®Google Scholar
• POWLES T, EELES R, ASHLEY S et al: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet (1998) 352:98–101.
   PubMed Web of Science ®Google Scholar
• VERONESI U, MAISONNEUVE P, COSTA A et al: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian tamoxifen prevention study. Lancet (1998) 352:93–97.
   Google Scholar
• CUMMINGS SR, ECKERT S, KRUEGER KA et al: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA (1999) 281(23):2189–2197.
   Google Scholar